SCHEMBL7089700

SCHEMBL7089700

CC(C)(C)C(=O)N(F)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.58
MEN1 O00255 4/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
NPSR1 Q6W5P4 2/20 0.41
ALDH1A1 P00352 2/20 0.39
TSHR P16473 2/20 0.39
GLA P06280 1/20 0.39
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.37
MAPT P10636 1/20 0.36
RIPK1 Q13546 2/20 0.36
DRD4 P21917 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36
NR1H3 Q13133 2/20 0.36
MLYCD O95822 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5498466 0.81 CES1 (0.45) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL245524 0.79 NPSR1 (0.41) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL9611270 0.78 KMT2A (0.62) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL8946139 0.77 KMT2A (0.60) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL3283283 0.77 KMT2A (0.60) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL1635424 0.76 NPSR1 (0.46) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL9474692 0.75 KMT2A (0.58) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL9500913 0.75 KMT2A (0.58) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL11583122 0.75 KMT2A (0.58) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL4741531 0.75 NPSR1 (0.50) KMT2AMEN1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303515-A2 TRICYCLIC 2-PYRIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS Bristol-Myers Squibb Pharma Company (US) 2003-04-23 EP disclosed
WO-2002008226-A2 TRICYCLIC 2-PYRIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-01-31 WO disclosed